# BTAIQ catalysts: BioXcel Therapeutics, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/btaiq/catalysts

> BioXcel Therapeutics, Inc. (BTAIQ) has no upcoming catalysts in this calendar. The latest recorded is the IGALMI® (dexmedetomidine) PDUFA date, November 14, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for BTAIQ?

BioXcel Therapeutics, Inc. (BTAIQ) has no upcoming catalysts in this calendar. The latest recorded is the IGALMI® (dexmedetomidine) PDUFA date, November 14, 2026. Press release filed with the SEC (EX-99): "FDA accepted sNDA for IGALMI® use in at-home (outpatient) setting; set Nov. 14, 2026, as PDUFA date" [Calendar and source filings](https://sec-api.dev/companies/btaiq/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001104659-26-061773, https://www.sec.gov/Archives/edgar/data/1720893/000110465926061773/tm2614679d1_ex99-1.htm (retrieved 2026-11-12). Last confirmed 2026-08-13. Cite: https://sec-api.dev/companies/btaiq/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | BioXcel Therapeutics, Inc. |
| Ticker | BTAIQ (OTC) |
| SEC CIK | 1720893 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/btaiq |

## Cash runway

Cash $12.8M as of 2026-06-30; quarterly burn $6.1M; about 6.3 months of runway at that rate (XBRL company facts, accession 0001104659-26-095965).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| April 5, 2022 | [IGALMI® (dexmedetomidine) FDA approval](https://sec-api.dev/pdufa/dexmedetomidine) | BTAIQ |  | completed, approved | "NDA215390 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20220405, review_priority STANDARD; sponsor_name BIOXCEL; product IGALMI (DEXMEDETOMIDINE HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215390%22)) |
| April 6, 2022 | [Talabostat FDA approval](https://sec-api.dev/pdufa/talabostat) | BTAIQ |  | completed, approved | "On April 6, 2022, we announced that the FDA approved IGALMITM sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1720893/000155837024015629/btai-20240930x10q.htm)) |
| June 29, 2023 | [IGALMI® (dexmedetomidine) topline data readout](https://sec-api.dev/pdufa/dexmedetomidine) | BTAIQ |  | completed, positive | "On June 29, 2023, we announced positive topline results from TRANQUILITY II, a randomized, double-blind, placebo-controlled, parallel group trial that evaluated the safety and efficacy of BXCL501 for the acute treatment of Alzheimer's-related agitation in adults 65 years and older with mild to moderate dementia in assisted living facilities ("ALFs") and residential care settings who required minimal assistance with activities of daily living." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1720893/000110465926036214/btai-20251231x10k.htm)) |
| June 25, 2024 | [IGALMI® (dexmedetomidine) topline data readout](https://sec-api.dev/pdufa/dexmedetomidine) | BTAIQ |  | completed, positive | "On June 25, 2024, we announced positive topline results from our post-marketing requirement study evaluating whether tolerance, tachyphylaxis, or withdrawal occur following repeat dosing of the 180 mcg (highest approved dose) of IGALMI®." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1720893/000110465926095965/btai-20260630x10q.htm)) |
| July 11, 2024 | [BioXcel Therapeutics, Inc. label expansion decision](https://sec-api.dev/companies/btaiq/catalysts) | BTAIQ |  | completed, approved | "On July 11, 2024, the Company entered into an amendment to the commercial supply agreement (the "Product Supply Agreement Amendment") that reduces the specified minimum annual payment over the next three years starting in the year ended 2024 and, thereafter, for a specified interval, provides for minimum annual payments to the extent that the Company receives approval of a supplemental new drug application (sNDA) or a new drug application (NDA) from the FDA for enumerated indications." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1720893/000110465926095965/btai-20260630x10q.htm)) |
| Sep 2024 | [IGALMI® (dexmedetomidine) trial start](https://sec-api.dev/pdufa/dexmedetomidine) | BTAIQ |  | completed | "In September 2024, the Company initiated patient enrollment in its SERENITY At-Home pivotal Phase 3 trial, evaluating the safety of BXCL501, the Company's investigational, proprietary, orally dissolving film formulation of dexmedetomidine, in the at-home setting for the acute treatment of agitation associated with bipolar disorders or schizophrenia." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1720893/000110465925019531/tm258055d1_8k.htm)) |
| November 14, 2024 | [BioXcel Therapeutics, Inc. earnings report](https://sec-api.dev/companies/btaiq/catalysts) | BTAIQ |  | completed | "Therapeutics Reports Third Quarter 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1720893/000110465924118261/tm2428378d1_ex99-1.htm)) |
| March 27, 2025 | [BioXcel Therapeutics, Inc. earnings report](https://sec-api.dev/companies/btaiq/catalysts) | BTAIQ |  | completed | "BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2024" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1720893/000110465925028776/tm2510663d1_ex99-1.htm)) |
| May 12, 2025 | [BioXcel Therapeutics, Inc. earnings report](https://sec-api.dev/companies/btaiq/catalysts) | BTAIQ |  | completed | "Conn., May 12, 2025 — BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today reported its financial results for the first quarter of 2025 and announced that its SERENITY At-Home pivotal Phase 3 safety trial for acute treatment of agitation associated with bipolar disorders or schizophrenia is fully enrolled." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1720893/000110465925047013/tm2514754d1_ex99-1.htm)) |
| Aug 2025 | [BioXcel Therapeutics, Inc. topline data readout](https://sec-api.dev/companies/btaiq/catalysts) | BTAIQ |  | scheduled | "Topline data from the study are expected to be released in August 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1720893/000155837025011158/btai-20250630x10q.htm)) |
| August 12, 2025 | [BioXcel Therapeutics, Inc. earnings report](https://sec-api.dev/companies/btaiq/catalysts) | BTAIQ |  | completed | "Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1720893/000110465925076501/tm2523230d1_ex99-1.htm)) |
| August 15, 2025 | [IGALMI® (dexmedetomidine) primary completion](https://sec-api.dev/pdufa/dexmedetomidine) | BTAIQ | Agitation,Psychomotor; Bipolar I Disorder; Bipolar II Disorder | completed | "NCT05658510 (Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-08-15 (ACTUAL); Lead Sponsor BioXcel Therapeutics Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05658510)) |
| August 20, 2025 | [IGALMI® (dexmedetomidine) NDA/BLA submission](https://sec-api.dev/pdufa/dexmedetomidine) | BTAIQ |  | scheduled | "The primary purpose of the pre-sNDA meeting, scheduled for August 20, 2025, is to gain alignment with the FDA regarding the content and format of the planned sNDA submission, which the Company is preparing." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1720893/000110465925069149/tm2521267d1_8k.htm)) |
| September 10, 2025 | [IGALMI® (dexmedetomidine) topline data readout](https://sec-api.dev/pdufa/dexmedetomidine) | BTAIQ |  | completed, positive | "On September 10, 2025, we further announced positive topline exploratory efficacy data from the SERENITY At-Home Pivotal Phase 3 safety trial, which demonstrated BXCL501 had sustained effects on agitation and consistent benefit with repeat dosing." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1720893/000110465926095965/btai-20260630x10q.htm)) |
| October 7, 2025 | [Bxcl501 sublingual film primary completion](https://sec-api.dev/pdufa/bxcl501-sublingual-film) | BTAIQ | Bipolar I Disorder; Bipolar II Disorder; Schizophrenia | completed | "NCT07116694 (Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar Disorder): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-10-07 (ACTUAL); Lead Sponsor BioXcel Therapeutics Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07116694)) |
| November 12, 2025 | [BioXcel Therapeutics, Inc. earnings report](https://sec-api.dev/companies/btaiq/catalysts) | BTAIQ |  | completed | "(Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today reported financial results for the third quarter of 2025 and provided an update on its late-stage agitation clinical development programs." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1720893/000110465925109732/tm2530979d1_ex99-1.htm)) |
| November 19, 2025 | [IGALMI® (dexmedetomidine) label expansion decision](https://sec-api.dev/pdufa/dexmedetomidine) | BTAIQ |  | completed, approved | "NDA215390 SUPPL-2 (Efficacy): submission_status AP, submission_status_date 20251119, review_priority STANDARD; sponsor_name BIOXCEL; product IGALMI (DEXMEDETOMIDINE HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215390%22)) |
| Q1 2026 | [IGALMI® (dexmedetomidine) NDA/BLA submission](https://sec-api.dev/pdufa/dexmedetomidine) | BTAIQ |  | scheduled | "Financial Results and Provides Update on Late-Stage Clinical Programs for Agitation in Bipolar, Schizophrenia, and Alzheimer's Disease sNDA submission expected in early Q1 2026 for expanded usage of IGALMI® in home setting based on positive data from the SERENITY-At Home trial" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1720893/000110465925109732/tm2530979d1_ex99-1.htm)) |
| January 20, 2026 | [IGALMI® (dexmedetomidine) NDA/BLA submission](https://sec-api.dev/pdufa/dexmedetomidine) | BTAIQ |  | completed | "On January 20, 2026, we announced we submitted a supplemental New Drug Application, or sNDA, to the FDA for IGALMI® in the at-home use setting for the acute treatment of agitation associated with bipolar disorders or schizophrenia." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1720893/000110465926061769/btai-20260331x10q.htm)) |
| March 5, 2026 | [IGALMI® (dexmedetomidine) topline data readout](https://sec-api.dev/pdufa/dexmedetomidine) | BTAIQ | opioid withdrawal symptoms in adults with opioid use disorder undergoing a methadone taper | completed, positive | "On March 5, 2026, the Company announced positive topline results from the Columbia Phase 2 investigator-sponsored trial evaluating BXCL501 for the treatment of opioid withdrawal symptoms in adults with opioid use disorder undergoing a methadone taper." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1720893/000110465926095965/btai-20260630x10q.htm)) |
| March 27, 2026 | [IGALMI® (dexmedetomidine) earnings report](https://sec-api.dev/pdufa/dexmedetomidine) | BTAIQ |  | completed | "Reports Fourth Quarter and Full-Year 2025 Financial Results as Company Prepares for Potential IGALMI® Approval in Outpatient Setting sNDA submitted seeking approval of IGALMI® in the at-home (outpatient) setting for the treatment of acute agitation associated with bipolar disorders or schizophrenia sNDA submission timeline supports potential approval as early as year-end 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1720893/000110465926035661/tm269970d1_ex99-1.htm)) |
| April 1, 2026 | [IGALMI® (dexmedetomidine) NDA/BLA acceptance](https://sec-api.dev/pdufa/dexmedetomidine) | BTAIQ |  | completed | "On April 1, 2026, we announced that the FDA has accepted our sNDA for approval of IGALMI® for at-home use in the acute treatment of agitation associated with bipolar disorders or schizophrenia." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1720893/000110465926095965/btai-20260630x10q.htm)) |
| May 15, 2026 | [BioXcel Therapeutics, Inc. earnings report](https://sec-api.dev/companies/btaiq/catalysts) | BTAIQ |  | completed | "(Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence ("AI") to develop transformative medicines in neuroscience, today provided a business update and reported financial results for the first quarter of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1720893/000110465926061773/tm2614679d1_ex99-1.htm)) |
| November 14, 2026 | [IGALMI® (dexmedetomidine) PDUFA date](https://sec-api.dev/pdufa/dexmedetomidine) | BTAIQ |  | scheduled | "FDA accepted sNDA for IGALMI® use in at-home (outpatient) setting; set Nov. 14, 2026, as PDUFA date" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1720893/000110465926061773/tm2614679d1_ex99-1.htm)) |

## Drugs

- [Bxcl501 sublingual film](https://sec-api.dev/pdufa/bxcl501-sublingual-film): Bipolar I Disorder
- [Talabostat](https://sec-api.dev/pdufa/talabostat): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/btaiq/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "BTAIQ catalysts: BioXcel Therapeutics, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/btaiq/catalysts

```bibtex
@misc{secapidev_companies_btaiq_catalysts_20261116,
  title        = {BTAIQ catalysts: BioXcel Therapeutics, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/btaiq/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_btaiq_catalysts_20261116","title":"BTAIQ catalysts: BioXcel Therapeutics, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/btaiq/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
